Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

References 222

1. 1.

   Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140-6.

   Not in our library10.1016/j.molonc.2012.01.010 (opens in a new tab)

2. 2.

   Pandha HS, Waxman J, Sikora K. Tumour markers. Br J Hosp Med. 1994;51(6):297-303.

   Not in our library

3. 3.

   He Yanli, Lu Haijun, Zhang Lijuan. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases. Prog Mol Biol Transl Sci. 2019;162:199-212.

   Not in our library10.1016/bs.pmbts.2019.01.001 (opens in a new tab)

4. 4.

   Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84.

   Not in our library10.1016/s0140-6736(11)60993-8 (opens in a new tab)

5. 5.

   Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;(11):1491-1505.

   Not in our library10.1016/j.annonc.2020.07.014 (opens in a new tab)

6. 6.

   Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, Verhaak RG. The landscape and therspeutic relevance of cancer-associated transcript. Oncogene. 2015;34(37):4845-54.

   Not in our library10.1038/onc.2014.406 (opens in a new tab)

7. 7.

   Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023.

   Not in our library10.1056/nejmoa2308795 (opens in a new tab)

8. 8.

   Varkaris A, Pazolli E, Gunaydin H, Wang Q, Pierce L, Boezio AA, DiPietro L, Frost A, Giordanetto F, Hamilton EP, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer DIscov. 2023.

   Not in our library10.1158/2159-8290.cd-23-0944 (opens in a new tab)

9. 9.

   Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-2070.

   Not in our library10.1056/nejmoa2214131 (opens in a new tab)

10. 10.

    Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-5.

    Not in our library10.1158/0008-5472.can-06-0191 (opens in a new tab)

11. 11.

    Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, et al. Encorafenib, Binimetinib, and Cetuximab in BRAFV600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632-1643.

    Not in our library10.1056/nejmoa1908075 (opens in a new tab)

12. 12.

    Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935-1948.

    Not in our library10.1056/nejmoa2306434 (opens in a new tab)

13. 13.

    Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-739.

    Not in our library10.1056/nejmoa1714448 (opens in a new tab)

14. 14.
    Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial · 2023

    No notice
15. 15.

    Harms PW, Frankel TL, Moutafi M, Rao A, Rimm DL, Taube JM, Thomas D, Chan MP, Pantanowitz L. Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists. Mod Pathol. 2023;36(7):100197.

    Not in our library10.1016/j.modpat.2023.100197 (opens in a new tab)

16. 16.

    Cohen R, Lee-Pullen T, Miller TJ, Meehan K, Fuller K, McCoy MJ. Optimising multiplex immunofluorescence staining for characterising the tumour immune micro-environment. Methods. 2023;219:48-57.

    Not in our library10.1016/j.ymeth.2023.09.004 (opens in a new tab)

17. 17.

    Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II. Multiplex Immunofluorescence Assays Methods. Mol Biol. 2020;2055:467-495.

    Not in our library10.1007/978-1-4939-9773-2_22 (opens in a new tab)

18. 18.

    Barrow E, Evans DG, McMahon R, Hill J, Byers R. A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome. J Clin Pathol. 2010;64(3):208-14.

    Not in our library10.1136/jcp.2010.084418 (opens in a new tab)

19. 19.

    Dowlatshahi S, Abdekhodaie MJ. Electrochemical prostate-specific antigen biosensors based on electroconductive nanomaterials and polymers. Clin Chim Acta. 2021;516:111-135.

    Not in our library10.1016/j.cca.2021.01.018 (opens in a new tab)

20. 20.

    Laraib U, Sargazi S, Rahdar A, Khatami M, Pandey S. Nanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review. Int J Biol Macromol. 2022;195:356-383.

    Not in our library10.1016/j.ijbiomac.2021.12.052 (opens in a new tab)

21. 21.

    Miedema J, Andea AA. Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis. Mod Pathol. 2020;33(7):1318-1330.

    Not in our library10.1038/s41379-020-0490-7 (opens in a new tab)

22. 22.

    Galogre M, Rodin D, Pyatnitskiy M, Mackelprang M, Koman I. A review of HER2 overexpression and somatic mutations in cancers. Crit Rev Oncol Hematol. 2023;186:103997.

    Not in our library10.1016/j.critrevonc.2023.103997 (opens in a new tab)

23. 23.

    Cen S, Liu Z, Pan H, Han W. Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188605.

    Not in our library10.1016/j.bbcan.2021.188605 (opens in a new tab)

24. 24.

    Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33-48.

    Not in our library10.1038/s41571-019-0268-3 (opens in a new tab)

25. 25.

    Kruglyak KM, Lin E, Ong FS. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. Adv Exp Med Biol. 2016;890:123-36.

    Not in our library10.1007/978-3-319-24932-2_7 (opens in a new tab)

26. 26.

    Paolillo C, Londin E, Fortina P. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine. Scand J Clin Lab Invest Suppl. 2016;245:S84-91.

    Not in our library10.1080/00365513.2016.1210331 (opens in a new tab)

27. 27.
    Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review · 2020

    No notice
28. 28.

    Oliveira LJC, Amorim LC, Megid TBC, de Resende CAA, Mano MS. Gene expression signatures in early breast cancer: Better together with clinicopathological features. Crit Rev Oncol Hematol. 2022;175:103708.

    Not in our library10.1016/j.critrevonc.2022.103708 (opens in a new tab)

29. 29.

    Zeng C, Zhang J. A narrative review of five multigenetic assays in breast cancer. Transl Cancer Res. 2022;11(4):897-907.

    Not in our library10.21037/tcr-21-1920 (opens in a new tab)

30. 30.

    Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40:586-597.

    Not in our library10.1200/jco.21.01497 (opens in a new tab)

31. 31.

    Passaro A, Brahmer J, Antonia S, Mok T, Peters S. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022;40:598-610.

    Not in our library10.1200/jco.21.01845 (opens in a new tab)

32. 32.

    Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345-362.

    Not in our library10.1038/s41571-021-00473-5 (opens in a new tab)

33. 33.

    Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353-1365.

    Not in our library10.1016/s1470-2045(20)30445-9 (opens in a new tab)

34. 34.

    Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.

    Not in our library10.1056/nejmoa2202170 (opens in a new tab)

35. 35.

    Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber W-J, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577-581.

    Not in our library10.1038/nature13988 (opens in a new tab)

36. 36.

    van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJA, Behjati S, Hilkmann H, el Atmioui D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31:e439-e442.

    Not in our library10.1200/jco.2012.47.7521 (opens in a new tab)

37. 37.

    Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 2019;9:1022-1035.

    Not in our library10.1158/2159-8290.cd-18-1494 (opens in a new tab)

38. 38.

    Linnemann C, van Buuren MM, Bies L, Verdegaal EME, Schotte R, Calis JJA, Behjati S, Velds A, Hilkmann H, el Atmioui D, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015;21:81-85.

    Not in our library10.1038/nm.3773 (opens in a new tab)

39. 39.

    Robbins PF, Lu Y-C, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747-752.

    Not in our library10.1038/nm.3161 (opens in a new tab)

40. 40.

    Tran E, Ahmadzadeh M, Lu Y-C, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350:1387-1390.

    Not in our library10.1126/science.aad1253 (opens in a new tab)

Cited by papers we hold 2

• Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives · 2025
  Not checked
• Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells · 2024
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.